median duration of LAMS placement was 44 days. No procedural or delayed LAMS related complications occurred.

Conclusion Appropriate pre-procedural cross-sectional imaging facilitates identification and treatment of underlying pseudoaneurysm in this complex patient group. Post procedure interval imaging enables quantification of the residual collection to determine the benefit of long term plastic stents or additional drainage procedure. Our experience suggests adherence to a rigorous imaging protocol may reduce the risk of complication associated with LAMS deployment.

Small bowel

OTH-5 FUNCTIONAL GASTROINTESTINAL DISORDERS AND ASSOCIATED HEALTH IMPAIRMENT IN INDIVIDUALS WITH COELIAC DISEASE

¹Sophie Parker*, ²Olafur Palsson, ¹David Sanders, ³Magnus Simren, ⁴Ami Sperber, ³Hans Tornblom, ²William Whitehead, ⁵Heidi Urwin, ¹Imran Aziz. ¹Academic Department Of Gastroenterology, Sheffield Teaching Hospitals, Sheffield, UK; ²Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina, USA; ³Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ⁴Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ⁵Coeliac UK, High Wycombe, Buckinghamshire, UK

10.1136/gutjnl-2021-BSG.25

Introduction Individuals with coeliac disease (CD) can experience persisting gastrointestinal symptoms despite adhering to a gluten-free diet (GFD). This may be due to functional gastrointestinal disorders (FGIDs), although there is little data on its prevalence and associated factors.

Methods An online health questionnaire was completed by adult members of Coeliac UK in October 2018. The survey included validated questions on Rome IV FGIDs, non-gastrointestinal somatic symptoms, anxiety, depression, quality of life, healthcare use, GFD duration and its adherence using the coeliac dietary adherence test score (with a value ≤ 13 indicating optimal adherence). The prevalence of FGIDs and associated health impairment in the coeliac cohort was compared against an age- and sex- matched population-based control group.

Results Of the 863 individuals with CD (73% female, mean age 61 years) all were taking a GFD for at least 1 year, with 96% declaring that they have been on the diet for over 2 years. The adherence to a GFD was deemed optimal in 61% (n=523) with the remaining 39% (n=340) non-adherent. Those adhering to a GFD fulfilled criteria for a FGID in approximately a half of cases, although this was significantly lower than non-adherent subjects (51% vs. 75%, OR 2.0; $p<0.001$). However, the prevalence of FGIDs in GFD-adherent subjects was significantly higher than in matched population-based controls (35%, OR 2.0; $p<0.001$). This was accounted for by functional bowel (46% vs. 31%, OR 1.9; $P<0.0001$) and anorectal disorders (14.5% vs. 9.3%, OR 1.7; $p=0.02$) but not functional esophageal (7.6% vs. 6.1%, $p=0.36$) or gastroduodenal disorders (8.7% vs. 7.4%, $p=0.47$). Finally, GFD-adherent subjects with FGIDs were significantly more likely, than their counterparts without FGIDs, to have abnormal levels of anxiety (5% vs. 2%, OR 2.8; $p=0.04$), depression (7% vs. 2%, OR 3.6; $p=0.01$), somatisation (31% vs. 8%, OR 5.1;

$p<0.0001$), increased healthcare use and reduced quality of life ($P<0.0001$).

Conclusion One-in-two people with CD, despite having been on a GFD for a number of years and demonstrating optimal adherence, have ongoing symptoms compatible with a Rome IV FGID. This is two-fold the odds of FGIDs seen in age- and sex- matched controls. The presence of FGIDs is associated with significant health impairment, including psychological co-morbidity. Addressing disorders of gut-brain interaction might improve outcomes in this specific group of patients.

OTH-6 REFRACTORY COELIAC DISEASE: PITFALLS OF T-CELL RECEPTOR CLONALITY AND INTRA-EPITHELIAL LYMPHOCYTE IMMUNOPHENOTYPING

Sebastian Povlsen*, Marc Ooft, Patrick Dubois. King's College Hospital, London, UK

10.1136/gutjnl-2021-BSG.26

Introduction Persistent villous atrophy (VA) occurs in up to 66% (Lebwohl et al 2013) following a diagnosis of coeliac disease (CD) despite a gluten free diet. Refractory coeliac disease (RCD) affects 0.3-4% of all patients with CD (Baggus et al 2019) and manifests persistent or recurrent classic malabsorptive symptoms of weight loss and diarrhoea. RCD is sub-classified by intra-epithelial lymphocyte (IEL) immunophenotyping and T-cell receptor (TCR) clonality into RCD1 and RCD2. RCD2 carries a high rate of progression to enteropathy-associated T-cell lymphoma (EATL) and roughly 50% 5-year mortality (Baggus et al 2019). However, the prognostic value of IEL immunophenotype and TCR clonality in patients not meeting strict clinical criteria for RCD is unclear.

Methods 17 consecutive patients referred for RCD assessment at King's College Hospital (KCH) were seen between September 2016 and November 2020. Retrospective data from 1998 to November 2020 were collected from patient records at KCH and referring hospitals, including demographics, blood tests, biopsies, IEL immunophenotyping and TCR clonality, diagnosis and clinical course.

Results Of 17 patients followed up for 104 patient years, 16 had persistent VA of which only 7 (44%) had malabsorptive

Abstract OTH-6 Table 1 Prevalence of abnormal IEL immunophenotype and TCR monoclonality at any point in follow-up period by diagnosis of all specimens in which TCR monoclonality was detected (n=38), 32% (n=12) had normal IEL counts. When tested, 92% (n=11) of specimens with normal IEL counts demonstrated TCR monoclonality

Abnormal IEL immunophenotype prevalence

Total	7 (42%)
NR	5 (56%)
RCD	1 (17%)
EATL	1 (100%)
Non-CD immune enteropathy	0
TCR monoclonality prevalence	
Total	12 (71%)
NR	7 (78%)
RCD	3 (50%)
EATL	1 (100%)
Non-CD immune enteropathy	1 (100%)